Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability
Table 5
(a) Response Surface Quadratic Model for particle size ( < 0.0001). (b) Response Surface Quadratic Model for PDI ( = 0.0272).
(a)
Response 1—PS (particle size) ANOVA for Response Surface Quadratic Model Analysis of Variance table (partial sum of squares—Type III)
Source
Sum of squares
df
Mean square
value
value Prob >
Model
64116.53
5
12823.31
42.26
<0.0001
Significant
—pressure
49886.40
1
49886.40
164.42
<0.0001
Significant
—number of cycles
10061.42
1
10061.42
33.16
0.0007
Significant
549.90
1
549.90
1.81
0.2202
Not significant
2681.72
1
2681.72
8.84
0.0207
Significant
73.55
1
73.55
0.24
0.6375
Not significant
Residual
2123.88
7
303.41
—
—
—
Lack of fit
1634.49
3
544.83
4.45
0.0915
Not significant
Pure error
489.39
4
122.35
—
—
—
Cor total
66240.41
12
—
—
—
—
(b)
Response 2—PDI (polydispersity index) ANOVA for Response Surface Quadratic Model Analysis of Variance table (partial sum of squares—Type III)